Trials / Completed
CompletedNCT04857957
Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CNTX-6016 in Healthy Subjects and a Single Cohort of Subjects With Painful Diabetic Neuropathy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Centrexion Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1b study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful diabetic neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral dose CNTX-6016 or oral dose Placebo | CNTX-6016 or Placebo |
Timeline
- Start date
- 2021-04-14
- Primary completion
- 2023-08-30
- Completion
- 2023-08-30
- First posted
- 2021-04-23
- Last updated
- 2025-07-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04857957. Inclusion in this directory is not an endorsement.